Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma
Authors:
- 12 June 2025
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 39 (12) , e70727
Abstract
The poor prognosis of clear cell renal cell carcinoma (ccRCC) is primarily attributed to inherent resistance and malignant progression, yet the underlying mechanism and effective strategies remain poorly understood. Renal drug transporters play an indispensable role in regulating the intracellular concentration of tumor cells. Therefore, this study aims to investigate the role of proton‐coupled oligopeptide transporter 2 (PEPT2) in ccRCC. PEPT2 was found to be downregulated in ccRCC tissues and cell lines, and its low expression was associated with an unfavorable prognosis in ccRCC patients. Overexpression of PEPT2 inhibited cell proliferation and metastasis both in vitro and in vivo. Furthermore, the transcriptional repression of PEPT2 was attributed to DNMT3A/B mediated methylation of its promoter, which could be reversed by the epigenetic inhibitor decitabine, leading to the restored expression and functional transport activity of PEPT2. Importantly, the combination treatment with decitabine (an epigenetic inhibitor) and a lenalidomide‐dipeptide conjugate (a substrate for PEPT2) significantly enhanced cytotoxicity against ccRCC cells both in vitro and in vivo. Our investigation into the epigenetic repression of PEPT2 promoters has revealed a significant role in the progression of ccRCC. Furthermore, our findings demonstrate that the combination of PEPT2‐targeted lenalidomide with epigenetic therapy effectively enhances cytotoxicity in ccRCC cells. This study provides compelling experimental evidence for the potential therapeutic benefit of targeting PEPT2 in the treatment of ccRCC.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LYY21H310009)
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
This publication has 37 references indexed in Scilit:
- Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinomaJournal of Physiology and Biochemistry, 2023
- Protein-restricted diet balanced for lysine, methionine, threonine, and tryptophan for nursery pigs elicits subsequent compensatory growth and has long term effects on protein metabolism and organ developmentAnimal Feed Science and Technology, 2020
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategiesDrug Resistance Updates, 2016
- Clinical Pharmacokinetics and Pharmacodynamics of LenalidomideClinical Pharmacokinetics, 2016
- Expression of proton‐coupled oligopeptide transporter (POTs) in prostate of mice and patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa)The Prostate, 2012
- Phase II trial of lenalidomide in patients with metastatic renal cell carcinomaInvestigational New Drugs, 2007
- The Epigenomics of CancerCell, 2007
- Phase II study of lenalidomide in patients with metastatic renal cell carcinomaCancer, 2006
- The proton oligopeptide cotransporter family SLC15 in physiology and pharmacologyPflügers Archiv - European Journal of Physiology, 2004
- Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidneyBiochimica et Biophysica Acta (BBA) - Biomembranes, 1995